Cabotegravir sodiumProduct ingredient for Cabotegravir

Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.^4,6,7 Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir,⁴ which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.^4,7

Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals.⁸ While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 ¹¹ and without the need for an oral lead-in period prior.⁷